| Literature DB >> 35568028 |
Rebecca A Drummond1, Jigar V Desai2, Emily E Ricotta2, Muthulekha Swamydas2, Clay Deming3, Sean Conlan3, Mariam Quinones4, Veronika Matei-Rascu5, Lozan Sherif5, David Lecky5, Chyi-Chia R Lee6, Nathaniel M Green2, Nicholas Collins7, Adrian M Zelazny8, D Rebecca Prevots2, David Bending5, David Withers5, Yasmine Belkaid9, Julia A Segre3, Michail S Lionakis10.
Abstract
Antibiotics are a modifiable iatrogenic risk factor for the most common human nosocomial fungal infection, invasive candidiasis, yet the underlying mechanisms remain elusive. We found that antibiotics enhanced the susceptibility to murine invasive candidiasis due to impaired lymphocyte-dependent IL-17A- and GM-CSF-mediated antifungal immunity within the gut. This led to non-inflammatory bacterial escape and systemic bacterial co-infection, which could be ameliorated by IL-17A or GM-CSF immunotherapy. Vancomycin alone similarly enhanced the susceptibility to invasive fungal infection and systemic bacterial co-infection. Mechanistically, vancomycin reduced the frequency of gut Th17 cells associated with impaired proliferation and RORγt expression. Vancomycin's effects on Th17 cells were indirect, manifesting only in vivo in the presence of dysbiosis. In humans, antibiotics were associated with an increased risk of invasive candidiasis and death after invasive candidiasis. Our work highlights the importance of antibiotic stewardship in protecting vulnerable patients from life-threatening infections and provides mechanistic insights into a controllable iatrogenic risk factor for invasive candidiasis. Published by Elsevier Inc.Entities:
Keywords: GM-CSF; IL-17A; antibiotics; invasive candidiasis; lymphocytes; trans-kingdom infections; vancomycin
Mesh:
Substances:
Year: 2022 PMID: 35568028 PMCID: PMC9283303 DOI: 10.1016/j.chom.2022.04.013
Source DB: PubMed Journal: Cell Host Microbe ISSN: 1931-3128 Impact factor: 31.316